1. Role of ErbB1 in the Underlying Mechanism of Lapatinib-Induced Diarrhoea: A Review
    Raja Nur Firzanah Syaza Raja Sharin et al, 2022, BioMed Research International CrossRef
  2. Incremental cost-effectiveness analysis of tyrosine kinase inhibitors in advanced non-small cell lung cancer with mutations of the epidermal growth factor receptor in Colombia
    Pieralessandro Lasalvia et al, 2021, Expert Review of Pharmacoeconomics & Outcomes Research CrossRef
  3. Fabrication of CaCO3-Coated Vesicles by Biomineralization and Their Application as Carriers of Drug Delivery Systems
    Chiho Miyamaru et al, 2022, International Journal of Molecular Sciences CrossRef
  4. Safety and CSF distribution of high-dose erlotinib and gefitinib in patients of non–small cell lung cancer (NSCLC) with brain metastases
    Bharati Shriyan et al, 2020, European Journal of Clinical Pharmacology CrossRef
  5. Cost-Effectiveness of 12 First-Line Treatments for Patients With Advanced EGFR Mutated NSCLC in the United Kingdom and China
    Haijing Guan et al, 2022, Frontiers in Oncology CrossRef

  6. A Systematic Review of Health Economic Evaluation on Targeted Therapies for First-Line Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC): Quality Evaluation


    Jie Zhao et al, 2020, Cancer Management and Research CrossRef
  7. FDX1 can Impact the Prognosis and Mediate the Metabolism of Lung Adenocarcinoma
    Zeyu Zhang et al, 2021, Frontiers in Pharmacology CrossRef